Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CRISPR Therapeutics

This page shows the latest CRISPR Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Following the amended agreement, Vertex will now lead the global development, manufacturing and commercialisation of the gene therapy CTX001, with support from CRISPR Therapeutics. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking

Latest news

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    In late March, Vertex was boosted further when its main challenger in the field, Proteostatis Therapeutics, reported disappointing results for its rival triple therapy candidate. ... These include alpha-1 antitrypsin deficiency and focal segmental

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease ... Meanwhile, CRISPR isn’t the only gene-editing

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing

  • Deal Watch May 2016 Deal Watch May 2016

    New CRISPR tech deals. After investing $335m in research support for a JV with CRISPR Therapeutics to discover, develop and commercialize new therapeutics to cure blood disorders, blindness, and congenital heart ... Financial details were not disclosed.

  • Deal Watch December 2015 Deal Watch December 2015

    440. Pieris (US). Roche. Collaboration, licence. Bispecific Anticalin-based protein therapeutics platform to discover immuno-oncology targets. ... 350. CRISPR Therapeutics (CH). Bayer Lifescience. Joint venture. Combining gene editing technology and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Lundberg most recently served as chief scientific officer of CRISPR Therapeutics, where he lead the development of the company’s first clinical trial application. ... Prior to CRISPR, he worked as head of translational medicine at Alexion

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform. ... Becker said: “I am excited to join the CRISPR Therapeutics

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors. ... Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...

Quick links